GlassScriptPhysician profile
Heather R Capps
NPI 1558793190
$17,391.57
in general payments reported to CMS, 2019-2025
32 companies · $4,495 in 2025
The $4,495 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,366 · 2022: $2,897 · 2023: $3,650 · 2024: $3,984 · 2025: $4,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,546.31 |
| Education | $582.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,254.72 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,647.38 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $1,642.08 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,524.44 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,310.85 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Genzyme Corporation | $1,219.29 | 2021-2025 | |
| Leo Pharma INC. | $866.84 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $806.51 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $705.95 | 2021-2025 | |
| Galderma Laboratories, L.P. | $695.29 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Arcutis Biotherapeutics, INC. | $693.11 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $509.58 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $450.51 | 2021-2025 | |
| Lilly USA, LLC | $419.96 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $413.01 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $396.93 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $281.23 | 2021-2025 | Opzelura |
| Almirall LLC | $243.46 | 2022-2025 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $241.10 | 2021 | |
| Organon LLC | $235.12 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.44 | 2023-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $101.51 | 2024-2025 | Ycanth |
| Biofrontera INC. | $93.75 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.97 | 2021-2023 | Siliq |
| Kerecis Limited | $85.93 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Sanofi-Aventis U.S. LLC | $84.49 | 2021 | |
| Amgen INC. | $74.03 | 2022-2024 | Otezla |
| Paratek Pharmaceuticals, INC. | $48.91 | 2024-2025 | Nuzyra |
| Strata Skin Sciences, INC. | $45.35 | 2024-2025 | Xtrac |
| Sebela Pharmaceuticals INC. | $40.27 | 2021 | |
| Kyowa Kirin, INC. | $19.36 | 2024 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $18.20 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.